Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase 4, Open-label, Single-arm, Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy

NCT03641560 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT03641560
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03641560 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase 4, Open-label, Single-arm, Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy
Lead sponsor
Astellas Pharma Inc
Phase
Phase 4
Overall status
Completed
Start date
September 19, 2018
Completion date
February 20, 2024
Enrollment
52 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration resistant prostate cancer